Jyong Biotech Ltd. announced the successful completion of a Phase II clinical trial for its lead investigational candidate, MCS-8. The company reported that the trial demonstrated positive outcomes in both oncological and metabolic health endpoints, specifically addressing prostate cancer risk and improvements in lipid profiles among the aging male population. The results of the Phase II study have already been presented. MCS-8, along with another candidate, MCS-2, remains under investigational status and has not received regulatory approval for commercial use in any jurisdiction. Jyong Biotech has also entered into non-binding agreements with pharmaceutical partners in South Korea and Vietnam to explore future commercialization opportunities for its pipeline products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653649-en) on February 12, 2026, and is solely responsible for the information contained therein.